ALLIANCE-A091401
Regimen
- Experimental
- Arm A: nivolumab 3 mg/kg Q2W monotherapy; Arm B: nivolumab 3 mg/kg + ipilimumab 1 mg/kg Q3W x 4 then nivolumab maintenance
- Control
- randomised non-comparative (no head-to-head p-value)
Population
Metastatic or unresectable sarcoma (bone and soft-tissue; included chondrosarcoma, dedifferentiated chondrosarcoma, and bone sarcoma subtypes alongside predominant STS histologies) after prior systemic therapy
Key finding
Combination nivo + ipi tripled response rate over nivo monotherapy but responses were soft-tissue-dominant. Bone sarcoma subtypes again contributed few responders — consistent with SARC028.
Source: PMID 29370992